About Corticobasal Degeneration
Corticobasal degeneration is a rare 4-repeat tauopathy causing neuronal loss and tau accumulation in the cortex and basal ganglia. The corticobasal syndrome (CBS) clinical presentation includes asymmetric limb rigidity and apraxia, the alien limb phenomenon, cortical sensory loss, myoclonus, and dystonia. CBD is pathologically defined at autopsy; clinically it overlaps with PSP, frontotemporal dementia, and Parkinson's disease. Disease progression is relentless with no approved therapies.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Corticobasal Degeneration trials.
Probable CBS diagnosis per Armstrong criteria is required — symptom asymmetry documentation is key
FDG-PET or MRI showing asymmetric cortical and basal ganglia changes supports eligibility confirmation
CSF and blood biomarkers (NfL, 4R-tau, phospho-tau) are used in trial stratification
Anti-tau therapeutic trials (same pipeline as PSP) may accept CBS as a phenotypic variant — confirm if the trial is pathology-defined or syndrome-defined
Patient Resources
Find recruiting Corticobasal Degeneration trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Corticobasal Degeneration. Updated daily.